Panelists from FDA, Genentech, and Minaris discussed raw material risk, supplier oversight, and at-risk release strategies for advanced therapies at the PDA/FDA Joint Regulatory Conference.
Athenesia Faggins
Advertisement
Athenesia Faggins, PhD, is director of analytical sciences at Minaris Advanced Therapies.
Articles by Athenesia Faggins
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Adalvo Acquires Enzene’s Romiplostim Biosimilar Program for ITP
2
Merck and Kelun’s Sac-TMT Extends Survival by Nearly 7 Months in Pretreated Endometrial Cancer
3
Aclaris’ TSLP/IL-4Rα Bispecific ATI-052 Shows Early Activity in Atopic Dermatitis and Asthma
4
The BioPharm Brief: Survival Gains, a Modest ADC Win, and CAR-T in Multiple Sclerosis
5